[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1107820T1 - Παραγωγα βενζοθειαζολιου για την θεραπευτικη αντιμετωπιση του διαβητη - Google Patents

Παραγωγα βενζοθειαζολιου για την θεραπευτικη αντιμετωπιση του διαβητη

Info

Publication number
CY1107820T1
CY1107820T1 CY20071101543T CY071101543T CY1107820T1 CY 1107820 T1 CY1107820 T1 CY 1107820T1 CY 20071101543 T CY20071101543 T CY 20071101543T CY 071101543 T CY071101543 T CY 071101543T CY 1107820 T1 CY1107820 T1 CY 1107820T1
Authority
CY
Cyprus
Prior art keywords
unsubstituted
substituted
benzothiazole derivatives
diabetes
group
Prior art date
Application number
CY20071101543T
Other languages
English (en)
Inventor
Pascale Gaillard
Jean-Pierre Gotteland
Pierre-Alain Vitte
Original Assignee
Laboratoires Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono Sa filed Critical Laboratoires Serono Sa
Publication of CY1107820T1 publication Critical patent/CY1107820T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά στη χρήση παραγώγων βενζοθειαζολίου για την παρασκευή ενός φαρμάκου για την θεραπευτική αντιμετώπιση διαταραχών του μεταβολισμού οι οποίες διαμεσολαβούνται από την ινσουλινοαντοχή ή την υπεργλυκαιμία, στις οποίες συμπεριλαμβάνεται ο διαβήτης τύπου II, η ανεπαρκής αντοχή στην γλυκόζη, η ινσουλινοαντοχή, η παχυσαρκία, το σύνδρομο πολυκυστικών ωοθηκών(PCOS).
CY20071101543T 2003-09-12 2007-12-04 Παραγωγα βενζοθειαζολιου για την θεραπευτικη αντιμετωπιση του διαβητη CY1107820T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102740 2003-09-12
EP04787110A EP1696909B1 (en) 2003-09-12 2004-09-08 Benzothiazole derivatives for the treatment of diabetes

Publications (1)

Publication Number Publication Date
CY1107820T1 true CY1107820T1 (el) 2013-06-19

Family

ID=34306921

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101543T CY1107820T1 (el) 2003-09-12 2007-12-04 Παραγωγα βενζοθειαζολιου για την θεραπευτικη αντιμετωπιση του διαβητη

Country Status (18)

Country Link
US (2) US20070088017A1 (el)
EP (1) EP1696909B1 (el)
JP (1) JP5021307B2 (el)
AT (1) ATE378047T1 (el)
AU (1) AU2004271740B2 (el)
CA (1) CA2534314C (el)
CY (1) CY1107820T1 (el)
DE (1) DE602004010178T2 (el)
DK (1) DK1696909T3 (el)
ES (1) ES2297494T3 (el)
HK (1) HK1096594A1 (el)
HR (1) HRP20070527T3 (el)
IL (1) IL174250A (el)
NO (1) NO20061600L (el)
PL (1) PL1696909T3 (el)
PT (1) PT1696909E (el)
SI (1) SI1696909T1 (el)
WO (1) WO2005025567A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838522B2 (en) * 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009001962A (es) 2006-08-24 2009-04-30 Univ Tennessee Res Foundation Acilanilidas substituidas y metodos de uso de las mismas.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100121057A1 (en) * 2007-04-17 2010-05-13 Merck Serono Sa Process for the Preparation of Piperazine Benzothiazoles
UA100527C2 (en) * 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
CN110840870A (zh) 2012-07-13 2020-02-28 Gtx公司 选择性雄激素受体调节剂在治疗转移性和难治性乳癌中的应用
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
WO2014114186A1 (zh) * 2013-01-24 2014-07-31 山东亨利医药科技有限责任公司 Jnk抑制剂
WO2017025980A2 (en) * 2015-08-12 2017-02-16 Shoolineuniversity Of Biotechnology And Management Sciences Novel benzothiazole derivatives with enhanced biological activity
US11970467B1 (en) 2023-10-13 2024-04-30 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound
US11905260B1 (en) 2023-10-13 2024-02-20 King Faisal University N′-(1-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1176269A (en) * 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
JP4589002B2 (ja) * 2001-12-07 2010-12-01 メルク セローノ ソシエテ アノニム 強皮症の治療のためのベンザゾール誘導体
AU2003233067B2 (en) * 2002-04-25 2009-01-08 Merck Serono Sa Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders

Also Published As

Publication number Publication date
DE602004010178D1 (de) 2007-12-27
SI1696909T1 (sl) 2008-02-29
HRP20070527T3 (en) 2007-12-31
AU2004271740A1 (en) 2005-03-24
ES2297494T3 (es) 2008-05-01
JP2007505083A (ja) 2007-03-08
CA2534314A1 (en) 2005-03-24
HK1096594A1 (en) 2007-06-08
IL174250A0 (en) 2006-08-01
ATE378047T1 (de) 2007-11-15
PT1696909E (pt) 2007-12-21
EP1696909A1 (en) 2006-09-06
EP1696909B1 (en) 2007-11-14
DK1696909T3 (da) 2008-01-02
PL1696909T3 (pl) 2008-04-30
CA2534314C (en) 2012-11-13
US20070088017A1 (en) 2007-04-19
WO2005025567A1 (en) 2005-03-24
IL174250A (en) 2011-01-31
AU2004271740B2 (en) 2010-10-28
JP5021307B2 (ja) 2012-09-05
DE602004010178T2 (de) 2008-09-11
US20140107116A1 (en) 2014-04-17
NO20061600L (no) 2006-04-07

Similar Documents

Publication Publication Date Title
CY1107820T1 (el) Παραγωγα βενζοθειαζολιου για την θεραπευτικη αντιμετωπιση του διαβητη
NO20061614L (no) Benzimidazolacetonitriler
ATE557030T1 (de) Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung
CY1123253T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν αναστολεα του sglt2, εναν αναστολεα της dpp-iv και προαιρετικα εναν επιπλεον αντιδιαβητικο παραγοντα και χρησεις αυτης
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
BRPI0412997A (pt) derivados de dióxido de tiazol-benzoisotiazol substituìdos, método para produzir os mesmos e seu uso
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
NO20083026L (no) Terapeutisk middel for diabetes
PA8566201A1 (es) Nuevos derivados de piridina y quinolina
BRPI0406761A (pt) Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
DE60325740D1 (de) Verwendung von protein-kinase-n-beta
BRPI0511757A (pt) derivados de arila e heteroarila substituìdos como moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a este
NO20080728L (no) Nye 1,4-benzotiazepin-1,1-dioksidderivater som har forbedrede egenskaper, fremgangsmate for fremstilling derav, medikamenter inneholdende nevnte forbindelsene og anvendelse derav
WO2010045303A3 (en) Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
CO6331470A2 (es) Antogonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
BRPI0911497B8 (pt) derivados de nip tiazol, seu processo de fabricação, medicamento, composição farmacêutica, e kit
MA28339A1 (fr) Derives de l'acide 7- amino-4-quinolone-3-carboxylique substitues de maniere heterocyclique, methode pour leur production et leur utilisation en tant que medicaments
NO20061599L (no) Benzoksazol acetonitriler
EA200400882A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ МЕТИЛЕНАМИДА В КАЧЕСТВЕ МОДУЛЯТОРОВ ПРОТЕИНТИРОЗИНФОСФАТАЗ ( PTPs )
NO20074639L (no) Krystallinsk base av trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
ATE455772T1 (de) Alkinylarylcarbonsäureamide
BRPI0417469B8 (pt) bifenil carboxamidas substituídas com n-aril piperidina, composição farmacêutica que os compreende e processo de preparação destes
BRPI0607558A2 (pt) derivados do ácido aminobutanóico, inibidor da carnitina palmitoil transferase(cpt)
DK1656139T3 (da) Aryldicarboxamider
TWI256952B (en) Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders